Distribution of adult AML patients in risk categories by IDH1 SNP status
| . | IDH1 SNP+ (n = 21) . | IDH1 SNP− (n = 165) . | ||
|---|---|---|---|---|
| N . | % . | N . | % . | |
| Favorable risk | ||||
| CBF AML | 0 | 0 | 20 | 12 |
| CN, FLT3− | 1 | 5 | 41 | 25 |
| Adverse risk | ||||
| CN, FLT3+ | 9 | 43 | 29 | 18 |
| Any other cytogenetics | 11 | 52 | 75 | 45 |
| . | IDH1 SNP+ (n = 21) . | IDH1 SNP− (n = 165) . | ||
|---|---|---|---|---|
| N . | % . | N . | % . | |
| Favorable risk | ||||
| CBF AML | 0 | 0 | 20 | 12 |
| CN, FLT3− | 1 | 5 | 41 | 25 |
| Adverse risk | ||||
| CN, FLT3+ | 9 | 43 | 29 | 18 |
| Any other cytogenetics | 11 | 52 | 75 | 45 |